Allergy Therapeutics: Grant of options

30th December 2016 | Allergy Therapeutics plc

Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the Company’s Long Term Incentive Plan (“LTIP”) the following conditional awards of shares of 0.1 pence each were made to Executive Directors at nominal cost of 0.1 pence each on 30 December 2016.

Manuel Llobet

Number of Conditional shares awarded – 1,690,000

Total conditional shares held under LTIPs – 3,380,000

 

Nick Wykeman

Number of Conditional shares awarded – 422,500

Total conditional shares held under LTIPs – 422,500

The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the satisfaction of performance conditions which include an earnings growth test over a three year testing period to 30 June 2019 and share price growth over the 3 year plan cycle.

Announcement in full


Allergy Therapeutics Company Wall

Allergy Therapeutics Investors Video on Five Minute Pitch TV

Click Image to view investors video, share price and more